Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Topiramate

FDA-approved product (tablet, oral), marketed as Eprontia, Qudexy Xr, Topamax and 3 more.

Registered studies
50+
Lab records
2
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Topiramate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Epilepsy
  • Lennox-Gastaut syndrome
  • Migraine disorder
  • Seizure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antiepileptics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA32.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis77.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 2 of 2 lab records
Open Topiramate in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Topiramate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia

    NCT00231621 · start 2001-05

    Registered record
    Registry ID
    NCT00231621
    Conditions
    Obesity; Hyperlipidemia; Hypertriglyceridemia
    Interventions
    topiramate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2001-05
    Completion
    2002-06
    Enrolment
    179

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Hyperlipidemia; Hypertriglyceridemia
    Interventiontopiramate
    PhasePhase 3
    Registry statusTerminated

  • A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy

    NCT00231634 · start 2001-05

    Registered record
    Registry ID
    NCT00231634
    Conditions
    Obesity; Diabetes Mellitus, Type 2; Diabetes Mellitus, Adult-Onset
    Interventions
    topiramate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2001-05
    Completion
    2002-11
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Diabetes Mellitus, Type 2; Diabetes Mellitus, Adult-Onset
    Interventiontopiramate
    PhasePhase 3
    Registry statusTerminated

  • A Study of Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension

    NCT00236665 · start 2001-03

    Registered record
    Registry ID
    NCT00236665
    Conditions
    Obesity; Hypertension
    Interventions
    topiramate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-03
    Completion
    2002-06
    Enrolment
    531

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Hypertension
    Interventiontopiramate
    PhasePhase 3
    Registry statusCompleted

  • A Pharmacokinetic Study of Lithium Before and During Topiramate Dosing in Bipolar Disorder Patients

    NCT00986128 · start 2001-03

    Registered record
    Registry ID
    NCT00986128
    Conditions
    Bipolar Disorder
    Interventions
    topiramate; topiramate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-03
    Completion
    2002-10
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    Interventiontopiramate; topiramate
    PhasePhase 1
    Registry statusCompleted

  • Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome

    NCT00004776 · start 1993-11

    Registered record
    Registry ID
    NCT00004776
    Conditions
    Lennox-Gastaut Syndrome
    Interventions
    topiramate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1993-11
    Completion
    Not recorded
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLennox-Gastaut Syndrome
    Interventiontopiramate
    PhasePhase 3
    Registry statusCompleted